

REMARKS

Claims 1-15 and 19 are pending. Claims 16-18 are canceled. Claims 11 and 14 are amended according to US practice for claim dependency. Claim 1 is amended for the dosage of Et 743. Support can be found on page 7, line 15 of the specification as filed. New claim 19 is added. Support for new claim 19 can be found in original claim 1. No new matter is added.

Response to Restriction Requirement

In response to the restriction requirement (page 2 of Office Action), Applicants elect Group I (claims 1-15), which also includes new claim 19.

In response to the election of species requirement (page 3 of Office Action), Applicants elect sarcoma as a species of “cancer” with claims 1-15 and 19 as readable upon the elected species. See also claims 14 and 15 which specifically list sarcoma. Applicants understand that upon allowance of a generic claim, the application will be entitled to consideration of claims to additional species of cancer.

AUTHORIZATION

The Commissioner is hereby authorized to charge any additional fees which may be required for consideration of this Amendment to Deposit Account No. **50-3732**, Order No. 13566.105020. In the event that an extension of time is required, or which may be required in addition to that requested in a petition for an extension of time, the Commissioner is requested to grant a petition for that extension of time which is required to make this response timely and is

hereby authorized to charge any fee for such an extension of time or credit any overpayment for an extension of time to Deposit Account No. **50-3732**, Order No. 13566.105020.

Respectfully submitted,
King & Spalding, LLP

Dated: November 13, 2007

By: /michael willis/
Michael A. Willis Reg. No. 53,913

Correspondence Address:
Customer Number 65989
King & Spalding
1185 Avenue of the Americas
New York, NY 10036-4003
(212) 556-2100 Telephone
(212) 556-2222 Facsimile